Special Late-Breaking Clinical Science Abstract: Hemodynamic Effects of Intravenous Istaroxime in Patients With SCAI Stage B Cardiogenic Shock: Insights From the SEISMiC Trial

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Consultant Fee/Honoraria/Speaker’s Bureau - AstraZenca; Vifor Pharma; Roche Diagnostics; Novartis; Boehringer Ingelheim
• Personal - Abbott Vascular